title: Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.
abstract: The systemic administration of recombinant interleukin-2 (IL-2) either alone or in combination with lymphokine activated killer cells is a new approach to the immunotherapy of metastatic cancer in man. Renal toxicity is often a dose-limiting side effect of IL-2 administration. This prospective study of 17 consecutive patients receiving parenteral high dose IL-2 documents a reversible syndrome of hypotension, oliguria, fluid retention, azotemia and very low urinary excretion of sodium (median FeNa of 0.04%). The median nadir urinary uric acid to urinary creatinine ratio during IL-2 therapy was 0.2. This IL-2 regimen induces a reversible renal hypoperfusion syndrome (pre-renal azotemia) without evidence of acute uric acid nephropathy. Hypophosphatemia [median serum phosphorus of 1.9 mg/dl (0.61 mmol/l)] prompted further study of tubular function. Urinary excretions of phosphorus, calcium and magnesium were very low. Arterial blood gases revealed hyperventilation without alkalemia. The hypophosphatemia probably reflects increased utilization of inorganic phosphorus by rapidly proliferating lymphoid cells.
authors.affiliation: Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
authors.forename: D E
authors.initials: DE
authors.lastname: Webb
authors.forename: H A
authors.initials: HA
authors.lastname: Austin
authors.forename: A
authors.initials: A
authors.lastname: Belldegrun
authors.forename: E
authors.initials: E
authors.lastname: Vaughan
authors.forename: W M
authors.initials: WM
authors.lastname: Linehan
authors.forename: S A
authors.initials: SA
authors.lastname: Rosenberg
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology*; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy; D006801:Humans; D007022:Hypotension / Q000209:etiology*; D007167:Immunotherapy / Q000009:adverse effects*; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D007694:Killer Cells, Natural; D008222:Lymphokines; D008875:Middle Aged; D009318:Natriuresis; D010710:Phosphates / Q000097:blood; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D014511:Uremia / Q000209:etiology*
chemical_list: D007376:Interleukin-2; D008222:Lymphokines; D010710:Phosphates; D011994:Recombinant Proteins